The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Official Title: A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Study ID: NCT01324479
Brief Summary: This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Highlands Oncology Group, Fayetteville, Arkansas, United States
University of Chicago SC, Chicago, Illinois, United States
Karmanos Cancer Institute Wayne St Karmanos, Detroit, Michigan, United States
Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States
University of Texas/MD Anderson Cancer Center Dept of Onc, Houston, Texas, United States
Novartis Investigative Site, Westmead, New South Wales, Australia
Novartis Investigative Site, Woolloongabba, Queensland, Australia
Novartis Investigative Site, Ottawa, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, La Tronche, , France
Novartis Investigative Site, LILLE Cédex, , France
Novartis Investigative Site, Strasbourg Cedex, , France
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Frankfurt, , Germany
Novartis Investigative Site, Freiburg, , Germany
Novartis Investigative Site, Gottingen, , Germany
Novartis Investigative Site, Hannover, , Germany
Novartis Investigative Site, Oldenburg, , Germany
Novartis Investigative Site, Hong Kong, , Hong Kong
Novartis Investigative Site, Shatin, New Territories, , Hong Kong
Novartis Investigative Site, Haifa, , Israel
Novartis Investigative Site, Kfar Saba, , Israel
Novartis Investigative Site, Ramat Gan, , Israel
Novartis Investigative Site, Tel Aviv, , Israel
Novartis Investigative Site, Ancona, AN, Italy
Novartis Investigative Site, Meldola, FC, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Reggio Emilia, RE, Italy
Novartis Investigative Site, Seoul, Gyeonggi Do, Korea, Republic of
Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of
Novartis Investigative Site, Utrecht, The Netherlands, Netherlands
Novartis Investigative Site, Amsterdam, , Netherlands
Novartis Investigative Site, Rotterdam, , Netherlands
Novartis Investigative Site, Oslo, , Norway
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Granada, Andalucia, Spain
Novartis Investigative Site, Oviedo, Asturias, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Zaragoza, , Spain
Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
Novartis Investigative Site, Songkhla, Hat Yai, Thailand
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR